REGN
Regeneron Pharmaceuticals, Inc.
Biotechnology · Healthcare · United States
805.97
close · 2026-08-13
value
75
cheaper than peers75
quality
86
stronger fundamentals86
ranked against
Biotechnology (commercial)
value
quality
101 peerswide variation
Value inputs
| measure | company | vs peers |
| price to sales | 5.26× | 78 |
| price to book | 2.55× | 77 |
| forward P/E | 13.41× | 66 |
| EV to EBITDA | 14.76× | 56 |
4 of 12 measures available
Quality inputs
| measure | company | vs peers |
| operating margin | 20.7% | 83 |
| return on equity | 14.5% | 79 |
| debt to equity | 8.6% | 68 |
| revenue growth | 19.0% | 42 |
4 of 4 measures available
Facts
| market cap | $83B |
| free cash flow | $3.27B |
| employees | 15,343 |
| first trade | 1991-04-02 |
| next earnings | 2026-07-30 |
| fundamentals updated | 2026-07-31 |